drugset / Trial / NCT06836284

The Evira Study: Additional Support During Obesity Treatment

NCT06836284

Recruiting 40 enrolled Karolinska Institutet Evira AB · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.

Timeline

Start
2026-02-13
Primary completion
2027-04-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Background Liraglutide Peptide
Background Semaglutide Peptide

Indications

No indication recorded.